| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 29.99M | 29.58M | 27.95M | 30.43M | 29.49M | 21.76M |
| Gross Profit | 4.88M | 3.25M | 4.71M | 8.15M | 8.96M | 4.52M |
| EBITDA | -2.82M | -4.72M | -3.94M | -4.10M | 223.65K | -282.87K |
| Net Income | -4.73M | -6.12M | -4.17M | -5.68M | -341.70K | -899.78K |
Balance Sheet | ||||||
| Total Assets | 22.25M | 21.18M | 20.58M | 21.99M | 26.88M | 24.95M |
| Cash, Cash Equivalents and Short-Term Investments | 2.02M | 720.00K | 2.08M | 4.72M | 7.59M | 5.63M |
| Total Debt | 9.44M | 7.21M | 2.94M | 2.39M | 1.81M | 1.96M |
| Total Liabilities | 16.13M | 14.20M | 9.94M | 7.62M | 7.48M | 5.98M |
| Stockholders Equity | 6.13M | 6.97M | 10.64M | 14.37M | 19.40M | 18.97M |
Cash Flow | ||||||
| Free Cash Flow | -3.52M | -10.36M | -5.45M | -3.10M | 1.92M | -181.22K |
| Operating Cash Flow | -1.06M | -6.59M | -2.44M | -2.10M | 2.86M | 67.35K |
| Investing Cash Flow | -2.19M | -1.66M | -1.45M | -767.82K | -605.00K | -70.99K |
| Financing Cash Flow | 4.30M | 6.89M | 1.25M | 0.00 | -299.06K | 814.86K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $36.97B | 27.27 | 31.01% | 3.07% | 4.71% | -23.03% | |
70 Outperform | $28.93B | 22.77 | 32.52% | 2.76% | -1.01% | 25.47% | |
66 Neutral | $2.66B | 29.26 | 10.48% | 0.96% | 0.34% | 0.85% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
62 Neutral | $70.85B | 20.51 | 13.07% | 3.53% | 4.13% | -5.19% | |
53 Neutral | $743.44M | ― | -55.07% | 3.17% | -10.40% | -1904.10% | |
41 Neutral | $13.18M | ― | -56.79% | ― | 8.09% | 17.25% |
On September 15, 2025, Allen C. Harper resigned from the board of Rocky Mountain Chocolate Factory, Inc. due to other professional responsibilities, not due to any disagreement with the company. Subsequently, the company received a notice from Nasdaq indicating non-compliance with certain corporate governance requirements due to the resignation, specifically regarding the composition of independent directors on the board and audit committee. The company plans to address this issue by appointing an additional independent director before the cure period ends in September 2026. This non-compliance does not currently affect the company’s stock listing or trading on Nasdaq.